AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Dyslipidemia is a critical risk factor for cardiovascular diseases
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
The integration of SAP S/4HANA Cloud will equip Cupid Limited with a comprehensive suite of integrated applications,
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Imfinzi also recommended for patients with mismatch repair deficient disease
Subscribe To Our Newsletter & Stay Updated